BioMarin opens only manufacturing site outside US in Co Cork, Ireland

BioMarin, a leading pharmaceutical company, has recently opened its new manufacturing plant in Cork, Ireland. With a total investment of €38 million, the new facility is expected to enhance the company’s global manufacturing capabilities for the treatment of rare genetic diseases. This significant investment is a reflection of BioMarin’s continued progress in developing innovative treatments for rare diseases that can transform the lives of patients worldwide. The new plant is expected to not only provide job opportunities but also boost the pharmaceutical industry in Cork. In this article, we’ll take a closer look at the significance of BioMarin’s new manufacturing plant in Ireland and its potential impact on the industry as a whole.


BioMarin, a pharmaceutical company, has inaugurated its new manufacturing site in Shanbally, Co Cork, which costs €38m. The facility is BioMarin’s only manufacturing site situated outside of the US. Taoiseach Leo Varadkar opened the new plant on Friday. The Shanbally facility will manufacture, package, and label BioMarin therapies for distributing globally. With this expansion, the firm will begin end-to-end manufacturing for several of its commercial products. BioMarin presently has eight marketed treatments, including its first gene therapy that was initiated last year. The Cork expansion has given the facility the ability to generate additional products as the company expands its pipeline. BioMarin previously established a site in Ireland in 2012 with only 12 employees. The firm now has over 500 workers in both Shanbally and Dublin, which functions as a headquarters for Canada and Europe.


In conclusion, the opening of BioMarin’s new €38m manufacturing plant in Cork is a major milestone for both the company and the local community. This state-of-the-art facility will not only produce life-changing medicines for patients around the world but also create job opportunities and drive economic growth in the region. We look forward to the continued success of BioMarin and the positive impact it will have on the healthcare industry and the Cork community.